• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Tenon Medical Inc.

    10/9/25 6:33:55 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care
    Get the next $TNON alert in real time by email
    S-8 1 ea0260579-s8_tenon.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on October 9, 2025

    Registration No. 333-          

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

    TENON MEDICAL, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   3841   45-5574718
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification No.)

     

    104 Cooper Court

    Los Gatos, CA 95032

    (408) 649-5760

    (Address of Principal Executive Offices)

     

    Tenon Medical, Inc. 2022 Equity Incentive Plan

    (Full title of the plan)

     

    Steven M. Foster

    Chief Executive Officer and President

    Tenon Medical, Inc.

    104 Cooper Court

    Los Gatos, CA 95032

    (Name and Address of Agent For Service)

     

    (408) 649-5760

    (Telephone number, Including Area Code, of Agent For Service)

     

    Copies of all communications, including all communications sent to the agent for service, should be sent to:

     

    Ross D. Carmel, Esq.

    Jeffrey P. Wofford, Esq.

     Anna Chaykina, Esq.
    Sichenzia Ross Ference Carmel LLP
    1185 Avenue of the Americas, 31st Floor

    New York, NY 10036
    (646) 838-1310

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging Growth Company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    This Registration Statement will become effective upon filing in accordance with Rule 462(a) under the Securities Act.

     

    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SECURITIES

     

    This Registration Statement on Form S-8 (the “Registration Statement”) registers 1,208,882 additional shares of common stock of Tenon Medical, Inc., Delaware corporation, (the “Registrant”) to be issued pursuant to the Registrant’s Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended (the “2022 Plan”).

     

    Pursuant to General Instruction E of Form S-8 under the Securities Act of 1933, as amended (“Securities Act”), this Registration Statement consists only of those items required by General Instruction E to Form S-8. Accordingly the Registrant incorporates by reference into this Registration Statement the contents of (1) the registration statement on Form S-8 (File No. 333-268360), filed with the Securities and Exchange Commission (the “SEC”) on November 15, 2022, relating to the registration of 29,092 shares of Registrant’s common stock, par value $0.001 per share (“Common Stock”) authorized for issuance under the 2022 Plan , and (2) the registration statement on Form S-8 (File No. 333-271778), filed with the SEC on May 9, 2023, relating to the registration of additional 5,618 shares of Common Stock authorized for issuance under the 2022 Plan, in each case, except for Items 3 and 8, which are being updated by this Registration Statement.

     

    Since May 9, 2023, the number of shares of Common Stock reserved and available for issuance under the 2022 Plan has been increased as follows: (i) by 13,002 shares pursuant to an automatic increase under the 2022 Plan as of January 1, 2024; (ii) by 137,500 shares as approved by the stockholders holding a majority of the voting power of the Registrant as of July 23, 2024, (iii) by 13,750 shares pursuant to an automatic increase under the 2022 Plan as of January 1, 2025, and (iv) by 1,138,495 shares as approved by the stockholders holding a majority of the voting power of the Registrant as of September 18, 2025 (“September 2025 Amendment”).

     

    This Registration Statement provides for the registration of an additional 1,208,882 shares of Common Stock issuable under the 2022 Plan. These 1,208,882 shares represent: (i) 70,387 shares of Common Stock, that are reserved and available for issuance under the 2022 Plan and have not been registered by the Registrant pursuant to previously filed registration statements on Form S-8, and (ii) 1,138,495 shares, reserved and available for issuance under the 2022 Plan pursuant to the September 2025 Amendment.

     

    The Common Stock share amounts stated above are presented on a post-split basis and reflect the 1-for-10 reverse stock split effected by the Registrant on November 2, 2023 and the 1-for-8 reverse stock split effected by the Registrant on September 6, 2024. 

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant is subject to the informational and reporting requirements of Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following documents, which are previously filed with the SEC, are incorporated into this Registration Statement by reference:

     

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 26, 2025;

     

    (b) the Registrant’s Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025, filed with the SEC on May 13, 2025 and August 13, 2025, respectively;

     

    (c) the Registrant’s Current Reports on Form 8-K filed with the SEC on March 12, 2025, March 27, 2025, March 28, 2025, August 7, 2025, and September 23, 2025; and

     

    (d) The description of the Registrant’s common stock, which is contained in a registration statement on Form 8-A filed with the SEC on April 26, 2022 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

     

    In addition, all documents subsequently filed by the Registrant with the SEC pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents. The Registrant is not incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the SEC.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    II-1

     

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description   Incorporated by Reference   Filed
    Herewith
      Schedule
    Form
      File
    Number
      Exhibit   Filing Date
    4.1   Second Amended and Restated Certificate of Incorporation of the Registrant, filed on April 10, 2023   S-3   333-271648   3.1   May 4, 2023    
    4.2   Certificate of Correction to Second Amended and Restated Certificate of Incorporation of the Registrant, filed on October 25, 2023                   X
    4.3   Amendment to Certificate of Incorporation Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on November 1, 2023   8-K   n/a   3.1   November 7, 2023    
    4.4   Amendment to Certificate of Incorporation Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on September 4, 2024                   X
    4.5   Certificate of Designations, Rights and Preferences for Series A Preferred Stock of the Registrant, filed on February 20, 2024   8-K   n/a   10.2   February 22, 2024    
    4.6  

    Amendment to Certificate of Designations, Rights and Preferences for Series A Preferred Stock, filed on September 5, 2024

              X
    4.7  

    Certificate of Designations, Rights and Preferences for Series B Preferred Stock, filed on September 5, 2024

              X
    4.8   Bylaws of the Registrant   S-1/A   333-260931   3.2   April 20, 2022    
    4.9   Tenon Medical, Inc. 2022 Equity Incentive Plan   S-1/A   333-260931   10.30   April 20, 2022    
    4.10   Amendment to Tenon Medical, Inc. 2022 Equity Incentive Plan, dated as of September 18, 2025                   X
    5.1   Opinion of Sichenzia Ross Ference Carmel LLP                   X
    23.1   Consent of Haskell & White LLP                   X
    23.2   Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1)                   X
    24.1   Power of Attorney (included in the signature pages hereto)                   X
    107   Filing Fee Table                   X

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of Los Gatos, State of California, on the 9th day of October 2025.

     

      TENON MEDICAL, INC.
         
      By: /s/ Steven M. Foster
      Name:  Steven M. Foster
      Title: Chief Executive Officer and President
    (Principal Executive Officer)

     

    KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints Steven M. Foster, Kevin Williamson, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or his or her substitutes or substitute may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Steven M. Foster   Chief Executive Officer, and President, Director  

    October 9, 2025

    Steven M. Foster   (Principal Executive Officer)    
             
    /s/ Kevin Williamson   Chief Financial Officer  

    October 9, 2025

    Kevin Williamson   (Chief Financial and Accounting Officer)    
             
    /s/ Richard Ferrari   Director  

    October 9, 2025

    Richard Ferrari        
             
    /s/ Richard Ginn  

    Chief Technology Officer and Director 

     

    October 9, 2025

    Richard Ginn      
             
    /s/ Stephen Hochschuler, MD   Director   

    October 9, 2025

    Stephen Hochschuler, MD        
             
    /s/ Ivan Howard   Director  

    October 9, 2025

    Ivan Howard        
             
    /s/ Kristine Jacques   Director  

    October 9, 2025

    Kristine Jacques        
             
    /s/ Robert Weigle   Director  

    October 9, 2025

    Robert Weigle        

     

     

    II-3

     

    Get the next $TNON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TNON
    SEC Filings

    View All

    Amendment: Tenon Medical Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - Tenon Medical, Inc. (0001560293) (Filer)

    10/17/25 5:15:27 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Tenon Medical Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Tenon Medical, Inc. (0001560293) (Filer)

    10/16/25 4:45:46 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Tenon Medical Inc.

    S-8 - Tenon Medical, Inc. (0001560293) (Filer)

    10/9/25 6:33:55 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $TNON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco

    LOS GATOS, CA / ACCESSWIRE / January 9, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that Chief Financial Officer Kevin Williamson will host one-on-one investor meetings in San Francisco, CA during the week of January 13th in accordance with the 43rd Annual J.P. Morgan Healthcare Conference.The J.P. Morgan Healthcare Conference is the industry's leading global investment forum, bringing together top executives, investors, and innovators across the healthcare ecosystem. With over 500 healthcare companies presenting, the event showcases groundbreaking advanc

    1/9/25 8:00:00 AM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Tenon Medical Reports Third Quarter 2024 Financial Results

    ~ 3Q Revenue of $0.9 Million, Consistent with Prior Quarter; Year to Date Revenue of $2.5 Million, Growth of 18.3% Compared to Prior Year ~~ Published Interim Analysis from MAINSAIL™ Study; Post-Market Study Supports the Safety and Efficacy of the Catamaran SI Joint Fusion System® Including Radiographic Proof of Fusion ~~ Initial Clinical Procedures Completed with New Catamaran SE Platform ~~ Granted Issuance of Three U.S. Patents ~~ Received Net Proceeds of ~$9.6 Million from Equity Financing Transactions ~ LOS GATOS, CA / ACCESSWIRE / November 13, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sac

    11/13/24 4:05:00 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Tenon Medical Announces Initial Clinical Cases Successfully Completed with Company's New Catamaran(R) SE SI Joint Fusion System

    ~ Procedures Completed in Various Spine & Pain Centers of Excellence Throughout the Country Including in Idaho, Pennsylvania, Minnesota, Arizona and Utah ~~Feedback From Initial Physician Users to Support Broader Market Introduction~ LOS GATOS, CA / ACCESSWIRE / October 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced completion of the initial clinical cases utilizing the Company's new Catamaran SE SI Joint Fixation Device. The new implant offers a 30% reduction in implant width as compared to the original Catamaran Fixation Device, providing physicians wi

    10/30/24 4:05:00 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $TNON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Foster Steven M

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    10/15/25 5:10:55 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Hochschuler Stephen

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    10/15/25 5:10:40 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Weigle Robert K

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    10/15/25 5:10:26 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $TNON
    Leadership Updates

    Live Leadership Updates

    View All

    Tenon Medical Appoints Medical Device Veteran, Kevin Williamson, Chief Financial Officer

    LOS GATOS, CA / ACCESSWIRE / August 27, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has appointed Kevin Williamson as Chief Financial Officer. Mr. Williamson's appointment succeeds the previously disclosed retirement of Steve Van Dick from the role of Chief Financial Officer.Mr. Williamson most recently served as the Chief Financial Officer at Accelus Inc., a medical device company focused on expandable spinal implant technology. In this role, Mr. Williamson was responsible for the finance organization, in addition to the investor relation

    8/27/24 4:05:00 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Tenon(R) Medical Appoints Kristine Jacques to its Board of Directors

    Experienced Medical Devices Industry Executive Joins Tenon's Board of DirectorsLOS GATOS, CA / ACCESSWIRE / March 28, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced that Kristine Jacques has been appointed as an independent member of the Company's Board of Directors on March 25, 2024, effective immediately. Following this appointment, Tenon Medical's Board of Directors consists of seven members, including four independent directors.During her impressive career spanning over 35 years, Ms. Jacques brings extensive experience in various executive leadership roles in

    3/28/24 8:00:00 AM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $TNON
    Financials

    Live finance-specific insights

    View All

    Tenon Medical, Inc. Announces Timing of Third Quarter 2024 Financial Results

    LOS GATOS, CA / ACCESSWIRE / October 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the third quarter 2024 ended September 30, 2024 after market close on Wednesday, November 13, 2024. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.Date:Wednesday, November 13, 2024Time:4:30 p.m. Eastern timeDial-in:1-800-717-1738International Dial-in:1-646-307-1865Webcast:TNON C

    10/30/24 8:00:00 AM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Tenon Medical Reports Second Quarter 2024 Financial Results

    ~ Second Quarter 2024 Revenue Increased 21% Year-Over-Year ~~ Surgical Procedures Increased 7% Year-Over-Year in the Second Quarter 2024 ~~ Gross Profit Margin of 52% Marks One Year of Generating Positive Gross Profit ~~ Publication of Post-Market Study Interim Analysis Now Imminent ~ LOS GATOS, CA / ACCESSWIRE / August 13, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today reported financial results for the second quarter ended June 30, 2024.Second Quarter 2024 and Subsequent HighlightsRevenue of $901,000 in the second quarter of 2024, a 21% increase over th

    8/13/24 4:05:00 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Tenon Medical, Inc. Announces Timing of Second Quarter 2024 Financial Results

    LOS GATOS, CA / ACCESSWIRE / July 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced plans to release financial results for the second quarter 2024 ended June 30, 2024 after market close on Tuesday, August 13, 2024. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.Date:Tuesday, August 13, 2024Time:4:30 p.m. Eastern timeDial-in:1-877-407-0792International Dial-in:1-201-689-8263Webcast:TNON Conference

    7/30/24 8:00:00 AM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $TNON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tenon Medical Inc.

    SC 13G - Tenon Medical, Inc. (0001560293) (Subject)

    10/4/24 1:21:56 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tenon Medical Inc.

    SC 13G - Tenon Medical, Inc. (0001560293) (Subject)

    8/8/24 4:07:29 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenon Medical Inc.

    SC 13G/A - Tenon Medical, Inc. (0001560293) (Subject)

    8/8/24 4:02:25 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care